In a case series of six patients with multidrug-resistant rheumatoid arthritis, the CD19xCD3-targeting bispecific T cell engager blinatumomab reduced disease activity and led to reductions in autoantibodies.
- Laura Bucci
- Melanie Hagen
- Ricardo Grieshaber-Bouyer